Clinical Trial Update: Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS [Phase 2, Phase 3]

View source ↗

Summary

Open-label extension study to evaluate the long-term safety and tolerability of ZYN002 (cannabidiol) in children and adolescents with Fragile X syndrome; Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• ZYN002

Snippet

Sponsor: Zynerba Pharmaceuticals, Inc. | Conditions: Fragile X Syndrome | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION